Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tysabri Re-Entry Hinges On Effective Risk Management: Diagnostics May Be Key

Executive Summary

Any risk management program tied to the market re-entry of Biogen Idec/Elan's Tysabri would likely include diagnostic procedures to test for early signs of progressive multifocal leukoencephalopathy

You may also be interested in...



Tysabri Registry Monthly Reports And Patient Checklist Follow-Up Advised

Biogen Idec should receive monthly reports from its Tysabri risk management patient registry on checklists filled out prior to infusion, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee recommended March 8

Tysabri Registry Monthly Reports And Patient Checklist Follow-Up Advised

Biogen Idec should receive monthly reports from its Tysabri risk management patient registry on checklists filled out prior to infusion, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee recommended March 8

Tysabri Resubmission: Early Safety Test For New Commissioner

The potential market re-entry for the multiple sclerosis therapy Tysabri (natalizumab) is likely to be one of the most high-profile safety issues facing the FDA under new leadership over the next six months

Related Content

Topics

UsernamePublicRestriction

Register

PS046214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel